GLP-1 family
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016
PMID: 27295427 · DOI: 10.1056/NEJMoa1603827
Summary
Multinational double-blind randomized trial (LEADER) in 9340 adults with type 2 diabetes and high cardiovascular risk; once-daily subcutaneous liraglutide 1.8 mg vs placebo, median 3.8 years. Primary endpoint: composite cardiovascular death, nonfatal MI, nonfatal stroke.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →GLP-1 SSingle-receptor incretin class agonist studied in incretin-pathway metabolic research.
Guides covering this compound
- How to read a peptide Certificate of AnalysisThe five numbers that actually matter on a peptide COA, what they mean, and the red flags that should make you choose a different supplier.7 min read
- HPLC vs mass spec vs amino acid analysis — what each test provesA practical guide to the three peptide QC methods, what each can prove and disprove, and why a complete QC profile requires all three.5 min read
- Made in the USA, and what that actually meansWhere our peptides are made, how we vet the active ingredient, and why independent per-lot testing matters more than any origin claim.3 min read
- How to evaluate a peptide supplier — a buyer's checklistTwelve questions every research customer should ask a peptide supplier before placing the first order, and what each answer reveals about the vendor's quality posture.4 min read
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021